Contusugene ladenovec within its licensed indication for the treatment of unresectable recurrent and/or refractory squamous cell carcinoma of the head and neck
Following on from information provided to NICE by the company in August 2009, the appraisal of Head and neck cancer - contusugene ladenovec [ID76] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- TA
- ID number:
- 76
- Referral date:
- 01 March 2009
- Topic area
- Cancer
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- TBC
- 1st appraisal committee meeting::
- TBC
Project Team
- Communications manager:
- TBC
- Executive Lead:
- TBC
- Project manager:
- Jeremy Powell
- Technical Lead:
- TBC
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
17 November 2022 | Following on from information provided to NICE by the company in August 2009, the appraisal of Head and neck cancer - contusugene ladenovec [ID76] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
17 November 2022 | Discontinued. Following on from information provided to NICE by the company in August 2009, the appraisal of Head and neck cancer - contusugene ladenovec [ID76] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
14 August 2009 | Appraisal suspended |
For further information on our processes and methods, please see our CHTE processes and methods manual